Discover the detailed record of transactions filed by Bouhours Guillaume, Directeur exécutif chargé de la Finance, des Achats et des Systèmes d’information chez bioMérieux. Insider active across 1 companies, notably BIOMERIEUX. Aggregated, 1 disclosures have been recorded. The latest transaction was filed on 27 June 2025 — Souscription. Regulator: AMF. All data is accessible without signup.
1 of 1 declaration
Guillaume Bouhours holds a key executive role at bioMérieux, the French listed in vitro diagnostics group and a global leader in infectious disease diagnostics. According to the company’s governance pages, he serves as Executive Vice President in charge of Finance, Purchasing and Information Systems, a remit that places him at the center of financial steering, resource allocation and the management of critical support functions. bioMérieux also identifies him as Chief Financial Officer, confirming his central role in financial discipline and in the company’s interface with capital markets. His career combines a strong engineering education with extensive senior experience in finance and industry. He graduated from École Polytechnique and École des Mines de Paris in 2000. He started his career at Morgan Stanley Investment Banking in London and Paris, before joining Sagard Private Equity Partners in 2004, where he became Investment Director in 2007. This early phase of his career gave him deep exposure to investment analysis, transaction work and strategic capital allocation. From 2010 to 2017, Bouhours served as Chief Financial Officer of Faiveley Transport, a company active in the rail transport sector. He also sat on the Management Board and Management Committee, broadening his experience beyond finance into corporate governance and operational leadership. Between 2017 and 2018, he became President of the Access and Mobility Division and President of the China Region at Wabtec Corporation, a role that strengthened his international management experience and his exposure to large-scale industrial operations. At bioMérieux, his responsibilities cover finance, purchasing and information systems, three functions that are especially strategic for a globally diversified healthcare company. In public remarks, he has highlighted the group’s solid operating performance, record profitability in 2021 and the company’s intention to reinvest a substantial share of its cash into the business. This reflects a management style focused on disciplined execution, resilience, innovation and long-term value creation. In addition to his executive duties, he serves as an independent director at Clariane, where he chairs the Audit Committee and sits on the Compensation and Human Resources Committee and the Appointments Committee. That board-level experience underscores his expertise in governance, internal control, financial oversight and risk management, making him a recognized profile in French corporate governance circles.